Latest News and Press Releases

Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, seven-figure revenue stream reflecting increased commercial...

CAMBRIDGE, UK – 20 May 2026 – 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final...

Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK,...

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

4basebio PLC ("4basebio" or the "Company") 4basebio Launches Enzymatic ssDNA Platform Overcomes critical manufacturing and performance bottlenecks associated with traditional chemical synthesis,...

Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Editing Efficiency

Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The "The Principles & Applications of CRISPR (July 7, 2026)" training has been added to ResearchAndMarkets.com's offering.This course offers an...

Pluristyx announces a new U.S. patent for iACT Stealth™ technology, enabling "cloaking" of cells to treat autoimmune diseases without immune suppression.

4basebio PLC ("4basebio" or the "Company") Cambridge, UK, 31 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics,...

Applied StemCell and Cellipont collaborate to enable seamless iPSC cell therapy development from early engineering to GMP production and scale-up.